Park Jinhyun, Choi Wonhui, Hwang Jinseub, Ah Young-Mi, Chung Byung Ha, Song Yun-Kyoung
College of Pharmacy, Daegu Catholic University, Gyeongsan, Republic of Korea.
Department of Statistics, Daegu University, Gyeongsan, Republic of Korea.
Front Pharmacol. 2025 May 13;16:1540576. doi: 10.3389/fphar.2025.1540576. eCollection 2025.
We aimed to evaluate the effect of different immunosuppressive regimens on the risk of major adverse cardiovascular events (MACEs) in kidney transplant recipients (KTRs).
This retrospective cohort study used nationwide claims data from the Korean Health Insurance Review and Assessment Service from between 2010 and 2021. Immunosuppressive medications were analyzed as time-dependent variables, and the primary outcome was MACEs, defined as a composite of myocardial infarction, coronary revascularization, ischemic stroke, and all-cause mortality.
A total of 8,056 KTRs were included in the analysis, with significant risk factors for MACEs identified as male sex, older age, longer dialysis duration, lower economic status, and greater comorbidity. At the time of the kidney transplant, 86.7% of the KTRs were administered standard triple therapy, after which various immunosuppressive regimens, including sirolimus-inclusive regimens, were employed. The risk of MACE was lower or comparable in KTRs standard triple therapy than in those receiving most other immunosuppressive regimens. However, corticosteroid withdrawal was associated with a significant reduction in cardiovascular risk, particularly in KTRs with preexisting diabetes or dyslipidemia.
These findings suggest that early consideration should be given to minimizing steroid use in KTRs with dyslipidemia or diabetes to optimize cardiovascular outcomes.
我们旨在评估不同免疫抑制方案对肾移植受者(KTRs)发生主要不良心血管事件(MACEs)风险的影响。
这项回顾性队列研究使用了韩国健康保险审查与评估服务机构2010年至2021年的全国索赔数据。免疫抑制药物被作为时间依赖性变量进行分析,主要结局是MACEs,定义为心肌梗死、冠状动脉血运重建、缺血性中风和全因死亡率的综合指标。
共有8056名KTRs纳入分析,确定的MACEs显著危险因素为男性、年龄较大、透析时间较长、经济状况较差和合并症较多。在肾移植时,86.7%的KTRs接受标准三联疗法,之后采用了包括含西罗莫司方案在内的各种免疫抑制方案。接受标准三联疗法的KTRs发生MACE的风险低于或与接受大多数其他免疫抑制方案的KTRs相当。然而,停用皮质类固醇与心血管风险显著降低相关,尤其是在已有糖尿病或血脂异常的KTRs中。
这些发现表明,对于血脂异常或糖尿病的KTRs,应尽早考虑尽量减少类固醇的使用,以优化心血管结局。